Theragenics Corporation(R) Announces Schedule for Fourth Quarter and Year End 2007 Conference Call

Theragenics Corporation (NYSE: TGX), a medical device company serving the prostate cancer treatment and surgical products markets, will release its fourth quarter and year end consolidated financial results before the market opens on Thursday, February 7, 2008. Following the release, the Company will host a conference call at 11:00 a.m. Eastern. To participate in the call, dial 800-538-9844 or 706-634-7274 and provide the conference ID # 32599268. This call is also being webcast and can be accessed via the Company’s Website. Log on to www.theragenics.com and select Investor Relations, company presentations. A replay will be available on the Website for one month. A phone replay will also be available until Midnight, February 14, by dialing 800-642-1687 or 706-645-9291 and entering the conference ID # 32599268. Theragenics Corporation (NYSE: TGX) operates two business segments: its brachytherapy seed business and its surgical products business. The brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer. Its surgical products business (www.cpmedical.com and www.galtmedical.com) manufactures and distributes wound closure and vascular access products. Wound closure products include sutures, needles and other surgical products with applications in, among other areas, urology, veterinary, cardiology, orthopedics, plastic surgery and dental. Vascular access includes introducers and guidewires used in the interventional radiology, interventional cardiology and vascular surgery markets. For additional information, call Theragenics’ Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.